Home » TorreyPines Discusses Results From Migraine Trial
TorreyPines Discusses Results From Migraine Trial
TorreyPines Therapeutics reported pharmacokinetic data from a Phase I maximum tolerated dose clinical trial of NGX426, the oral prodrug of tezampanel used to treat migraines.
The double-blind, placebo-controlled trial enrolled healthy adult volunteers in sequential, dose-escalating cohorts. The Phase I data show that single, oral doses of NGX426 from 40 mg to 90 mg are safe and well tolerated, according to TorreyPines.
The company is amending the Phase I clinical trial protocol to extend the dosing range beyond 90 mg to identify the maximum tolerated dose.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May